These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 28625716)
41. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia. Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122 [TBL] [Abstract][Full Text] [Related]
42. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511 [TBL] [Abstract][Full Text] [Related]
43. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning. Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384 [TBL] [Abstract][Full Text] [Related]
44. Prolyl hydroxylase 2 (PHD2) inhibition protects human renal epithelial cells and mice kidney from hypoxia injury. Fang Y; Zhang H; Zhong Y; Ding X Oncotarget; 2016 Aug; 7(34):54317-54328. PubMed ID: 27527871 [TBL] [Abstract][Full Text] [Related]
45. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Böttcher M; Lentini S; Arens ER; Kaiser A; van der Mey D; Thuss U; Kubitza D; Wensing G Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006 [TBL] [Abstract][Full Text] [Related]
46. Nonhypoxic pharmacological stabilization of Hypoxia Inducible Factor 1α: Effects on dopaminergic differentiation of human neural stem cells. Hey SM; Jensen P; Ryding M; Martínez Serrano A; Kristensen BW; Meyer M Eur J Neurosci; 2019 Feb; 49(4):497-509. PubMed ID: 30471165 [TBL] [Abstract][Full Text] [Related]
48. Molecular characterization and mRNA expression of HIF-prolyl hydroxylase-2 (phd2) in hypoxia-sensing pathways from Megalobrama amblycephala. Wang H; Huang C; Chen N; Zhu K; Chen B; Wang W; Wang H Comp Biochem Physiol B Biochem Mol Biol; 2015 Aug; 186():28-35. PubMed ID: 25868626 [TBL] [Abstract][Full Text] [Related]
49. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449 [TBL] [Abstract][Full Text] [Related]
50. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway. Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R Skelet Muscle; 2016; 6():5. PubMed ID: 26949511 [TBL] [Abstract][Full Text] [Related]
51. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. Higashijima Y; Tanaka T; Nangaku M Expert Opin Drug Discov; 2013 Aug; 8(8):965-76. PubMed ID: 23642028 [TBL] [Abstract][Full Text] [Related]
57. Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia. Soni H Med Hypotheses; 2014 May; 82(5):547-50. PubMed ID: 24581673 [TBL] [Abstract][Full Text] [Related]
58. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Gupta N; Wish JB Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135 [TBL] [Abstract][Full Text] [Related]